US Bancorp
PYXS icon

US Bancorp’s Pyxis Oncology PYXS Stock Holding History

US Bancorp’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-94
Closed -$108 – 4296
2025
Q4 		$108 Buy
+94
New +$332 ﹤0.01% 3997

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

US Bancorp's PYXS Position: Q1 2026 in Review

US Bancorp sold out of Pyxis Oncology (PYXS) in Q1 2026, closing a stake of 94 shares — an estimated $108 sold.

US Bancorp first reported a position in PYXS in Q4 2025 and held it in 1 quarter. The position peaked at $108 in Q4 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • US Bancorp reported no remaining Pyxis Oncology position as of Q1 2026 after selling out during the quarter.
  • US Bancorp sold 94 Pyxis Oncology shares in Q1 2026, an estimated $108.
  • US Bancorp first reported a position in Pyxis Oncology in Q4 2025 and held it in 1 quarter.
  • US Bancorp's Pyxis Oncology position peaked at $108 in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.